|
GSK PLC on Saturday announced positive interim results from its B-Clear phase IIb trial, which tested bepirovirsen as a treatment of chronic hepatitis B.
Interim analysis from the trial showed that bepirovirsen had reduced levels of the hepatitis B surface antigen and hepatitis B virus DNA after 24 weeks of treatment in people with hepatitis B.
Chronic hepatitis B is a viral infection of the liver, and occurs when the body's immune system is unable to fight off the virus, and can progress to further complications including cirrhosis and liver cancer.
Looking ahead, GSK is planning to evaluate bepirovirsen as a monotherapy, in a phase III trial which is expected to start n the first half of 2023.
‘Chronic hepatitis B affects nearly 300 million people with approximately 900,000 patients dying each year from its associated complications. These encouraging data support further investigation of bepirovirsen, both as monotherapy and in combination, as a potentially transformative new treatment option for patients with chronic hepatitis B,’ said Chris Corsico, senior vice president of Development at GSK.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
